Selected article for: "clinical presentation and control group"

Author: Komici, Klara; Bianco, Antonio; Perrotta, Fabio; Dello Iacono, Antonio; Bencivenga, Leonardo; D’Agnano, Vito; Rocca, Aldo; Bianco, Andrea; Rengo, Giuseppe; Guerra, Germano
Title: Clinical Characteristics, Exercise Capacity and Pulmonary Function in Post-COVID-19 Competitive Athletes
  • Cord-id: btteneni
  • Document date: 2021_7_9
  • ID: btteneni
    Snippet: Background: Limited evidence exists regarding adverse modifications affecting cardiovascular and pulmonary function in physical active adults affected by COVID-19, especially in athletic populations. We aimed to describe the clinical presentation of COVID-19 in a cohort of competitive athletes, as well as spirometry and echocardiography findings and cardio-respiratory performance during exercise. Methods: Twenty-four competitive athletes with COVID-19 were recruited for this study after ending s
    Document: Background: Limited evidence exists regarding adverse modifications affecting cardiovascular and pulmonary function in physical active adults affected by COVID-19, especially in athletic populations. We aimed to describe the clinical presentation of COVID-19 in a cohort of competitive athletes, as well as spirometry and echocardiography findings and cardio-respiratory performance during exercise. Methods: Twenty-four competitive athletes with COVID-19 were recruited for this study after ending self-isolation and confirmation of negative laboratory results. All athletes underwent clinical evaluation, spirometry, echocardiography and cardiopulmonary exercise testing (CPET). These data were compared to a group of healthy control athletes. Results: Anosmia was the most frequent symptom present in 70.83% patients, followed by myalgia, fatigue and ageusia. The most frequent persisting symptoms were anosmia 11 (45.83%) and ageusia 8 (33.33%). Compared to controls, COVID-19 patients presented lower FEV1%: 97.5 (91.5–108) vs. 109 (106–116) p = 0.007. Peak Oxygen Uptake (VO(2)) in COVID-19 patients was 50.1 (47.7–51.65) vs. 49 (44.2–52.6) in controls (p = 0.618). Conclusions: Reduced exercise capacity was not identified and pulmonary and cardiovascular function are not impaired during early recovery phase in a population of physical active adults except FEV1 reduction.

    Search related documents:
    Co phrase search for related documents
    • activity induce and long covid: 1
    • activity induce and lung disease: 1
    • activity induce and lung function: 1
    • acute inflammation and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute inflammation and long term impairment: 1
    • acute inflammation and long term short: 1, 2, 3, 4
    • acute inflammation and lung capacity: 1, 2
    • acute inflammation and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute inflammation and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute inflammation and lung macrophage: 1, 2, 3, 4, 5
    • additional laboratory and long covid: 1
    • additional laboratory and lung disease: 1
    • long covid and lung capacity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • long covid and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • long covid and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • long covid suggest and lung disease: 1
    • long term impairment and lung capacity: 1, 2
    • long term impairment and lung disease: 1
    • long term impairment and lung function: 1, 2